Tonghua Dongbao H1 Net Profit Up 37.32% to RMB296 Million
Tonghua Dongbao reported a 37.32% year-on-year increase in net profit attributable to shareholders for the first half of 2026, reaching RMB296 million. Revenue rose 11.13% to RMB1.553 billion, driven by significant growth in insulin analogue product sales.
Tonghua Dongbao released its semi-annual report for 2026. During the reporting period, the company achieved operating revenue of RMB1.553 billion, an increase of 11.13% compared with the same period in 2025. Net profit attributable to shareholders of the listed company reached RMB296 million, up 37.32% year on year. Basic earnings per share stood at RMB0.15. During the reporting period, sales of insulin analogue products grew significantly, boosting domestic revenue.